How many drugs treat Pulmonary emphysema?

Drug Landscape tracks 10 marketed treatments for Pulmonary emphysema (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Pulmonary emphysema?

Most recent: Bupivacaine Hydrochloride And Epinephrine — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pulmonary-emphysema.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pulmonary emphysema — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary emphysema (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary emphysema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Breo Ellipta	VILANTEROL	Glaxo Grp Ltd	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2013-01-01
Incruse Ellipta	UMECLIDINIUM	Glaxo Grp England	Anticholinergic	Muscarinic acetylcholine receptor M4	2013-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	Corticosteroid	Glucocorticoid receptor	2007-01-01
Brovana	ARFORMOTEROL	Lupin	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2006-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
Foradil	FORMOTEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Tornalate	BITOLTEROL	Sanofi	bitolterol	Beta-2 adrenergic receptor	1984-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Epipen	epinephrine	Pfizer Inc.	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor	1948-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-30 — Bupivacaine Hydrochloride And Epinephrine · FDA · approved · US
2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Pulmonary emphysema
Fundacio Privada Mon Clinic Barcelona · 2 drugs in Pulmonary emphysema
Glaxo Grp England · 2 drugs in Pulmonary emphysema
Pfizer Inc. · 2 drugs in Pulmonary emphysema
Glaxo Grp Ltd · 1 drug in Pulmonary emphysema
Haleon Us Holdings · 1 drug in Pulmonary emphysema
Lupin · 1 drug in Pulmonary emphysema
Mundipharma Research Limited · 1 drug in Pulmonary emphysema
Novartis · 1 drug in Pulmonary emphysema
Pfizer · 1 drug in Pulmonary emphysema
Sanofi · 1 drug in Pulmonary emphysema
Tanta University · 1 drug in Pulmonary emphysema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary emphysema:

Cite this brief

Drug Landscape (2026). Pulmonary emphysema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-emphysema. Accessed 2026-06-10.

Pulmonary emphysema full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing